Pille Harrison

Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial

Séverine Vermeire, Stefan Schreiber, Robert Petryka et al. · The Lancet · 2016 · 432 citations

Fitzroy Study, Gastroenterology, Clinical Gastroenterology +4

Rheumatoid arthritis association at 6q23

Wendy Thomson, Anne Barton, Xiayi Ke et al. · Nature Genetics · 2007 · 385 citations · Full text

Rheumatoid Disorder, Rheumatology, Autoimmune Disease +8

Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk

Soumya Raychaudhuri, Brian Thomson, Elaine F. Remmers et al. · Nature Genetics · 2009 · 350 citations

Rheumatoid Disorder, Rheumatology, Genetic Variants +12

Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)

René Westhovens, Peter C. Taylor, Rieke Alten et al. · Annals of the Rheumatic Diseases · 2016 · 227 citations · Full text

Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)

Arthur Kavanaugh, Joel M. Kremer, L Ponce et al. · Annals of the Rheumatic Diseases · 2016 · 226 citations · Full text